COVIDx-US: An Open-Access Benchmark Dataset of Ultrasound Imaging Data for AI-Driven COVID-19 Analytics.

BACKGROUND: The Coronavirus Disease 2019 (COVID-19) pandemic continues to have a devastating effect on the health and well-being of the global population. Apart from the global health crises, the pandemic has also caused significant economic and financial difficulties and socio-physiological implications. Effective screening, triage, treatment planning, and prognostication of outcome play a key role in controlling the pandemic. Recent studies have highlighted the role of point-of-care ultrasound imaging for COVID-19 screening and prognosis, particularly given that it is non-invasive, globally available, and easy-to-sanitize. COVIDx-US Dataset: Motivated by these attributes and the promise of artificial intelligence tools to aid clinicians, we introduce COVIDx-US, an open-access benchmark dataset of COVID-19 related ultrasound imaging data. The COVIDx-US dataset was curated from multiple data sources and its current version, i.e., v1.5., consists of 173 ultrasound videos and 21,570 processed images across 147 patients with COVID-19 infection, non-COVID-19 infection, other lung diseases/conditions, as well as normal control cases. CONCLUSIONS: The COVIDx-US dataset was released as part of a large open-source initiative, the COVID-Net initiative, and will be continuously growing, as more data sources become available. To the best of the authors' knowledge, COVIDx-US is the first and largest open-access fully-curated benchmark lung ultrasound imaging dataset that contains a standardized and unified lung ultrasound score per video file, providing better interpretation while enabling other research avenues such as severity assessment. In addition, the dataset is reproducible, easy-to-use, and easy-to-scale thanks to the well-documented modular design.

A 53-year-old man with dyspnoea, respiratory failure, consistent with infliximab-induced acute interstitial pneumonitis after an accelerated induction dosing schedule.

A 53-year-old man with ulcerative colitis (UC) suffered fatal acute interstitial pneumonitis (AIP) post completing an accelerated infliximab induction course. This is the first case reported in this setting. A literature review found four similar cases of infliximab-induced interstitial lung disease in the setting of treating patients with UC using standard infliximab regimens had successful treatment of the subjects post infliximab discontinuation. Unfortunately, the patient we are presenting, who had an accelerated infliximab induction course, did not survive. Although a prior small trial along more recent new small studies continue to show a benefit in reducing the need for early colectomy with the accelerated infliximab induction regimen as salvage therapy, it should be used cautiously until more safety data are available. Further larger trials are required to investigate rare side effects that may be associated with this regimen such as rapidly progressive lung toxicity as seen in this patient.